<DOC>
	<DOCNO>NCT00730691</DOCNO>
	<brief_summary>The purpose study determine safety efficacy vortioxetine , daily ( QD ) , adult generalize anxiety disorder .</brief_summary>
	<brief_title>Efficacy Vortioxetine ( Lu AA21004 ) Treating Generalized Anxiety Disorder</brief_title>
	<detailed_description>Participants study randomly assign receive either 2.5 mg , 5 mg 10 mg vortioxetine , daily , 60 mg duloxetine daily , placebo daily eight week . Participants see weekly first 2 week treatment , every 2 week end 8-week treatment period . Participants complete 8-week treatment period enter 2-week discontinuation period order assess potential discontinuation symptom . Total commitment time 12 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Has primary diagnosis generalize anxiety disorder accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR® ) criterion ( classification code 300.02 ) . Has Hamilton Anxiety Scale total score ≥ 20 . Has Hamilton Anxiety Scale score ≥2 item 1 ( anxious mood ) item 2 ( tension ) . Has MontgomeryÅsberg Depression Rating Scale total score ≤16 . Had receive investigational compound &lt; 30 day Screening 5 halflives prior Screening , whichever longer . Received Lu AA21004 previous clinical study . Was study site employee , immediate family member ( ie , spouse , parent , child , sibling ) study site employee involve conduct study . Has 1 follow : Any current psychiatric disorder Generalized Anxiety Disorder define DSMIVTR® ( assess Mini International Neuropsychiatric Interview [ MINI ] ) . Current past history manic hypomanic episode , schizophrenia psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Any substance disorder ( except nicotine caffeine ) within previous 6 month define DSMIVTR® must negative urine drug screen prior Baseline . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc ) . Any Axis II disorder might compromise study . Has know sensitivity duloxetine . Is take excluded medication Has significant risk suicide accord investigator 's opinion score ≥5 item 10 ( suicidal thought ) MontgomeryÅsberg Depression Rating Scale make suicide attempt previous 6 month . Has previously fail respond adequate treatment selective serotonin reuptake inhibitor and/or serotoninnorepinephrine reuptake inhibitor . Has receive electroconvulsive therapy within 6 month prior Screening . Is currently receive formal cognitive behavioral therapy , systematic psychotherapy , plan initiate therapy study . Has know history currently increase intraocular pressure risk acute narrowangle glaucoma . Has clinically significant unstable illness , example , hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , infectious , skin subcutaneous tissue disorder , metabolic disturbance . Has alanine aminotransferase , aspartate aminotransferase , total bilirubin level &gt; 1.5 time upper limit normal . Has serum creatinine level &gt; 1.5 upper limit normal . Has previous history cancer remission le 5 year . Hasclinically significant abnormal vital sign determine investigator . Has history lack response previous adequate treatment duloxetine Generalized Anxiety Disorder episode . Has 1 laboratory value outside normal range , base blood urine sample take Screening Visit Has thyroid stimulate hormone value outside normal range . Has abnormal electrocardiogram . disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . The patient , opinion investigator , unlikely comply clinical study protocol unsuitable reason . Had previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>Mood Disorder</keyword>
	<keyword>Affective Disorder</keyword>
	<keyword>Anxiety Disorder</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>